ARMATA PHARMACEUTICALS, INC. Interest Expense
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Interest Expense of $2.72 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-08-13
- ARMATA PHARMACEUTICALS, INC. interest expense for the quarter ending 2024-06-30 was $2.72M.
- ARMATA PHARMACEUTICALS, INC. interest expense for the quarter ending 2024-03-31 was $1.82M.
- ARMATA PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-09-30 was $1.18M.
- ARMATA PHARMACEUTICALS, INC. interest expense for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. interest expense for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- ARMATA PHARMACEUTICALS, INC. interest expense for fiscal 2021 was $64.00K, a 89.81% decline from fiscal 2020.
- ARMATA PHARMACEUTICALS, INC. interest expense for fiscal 2020 was $628.00K, a 32.55% decline from fiscal 2019.
- ARMATA PHARMACEUTICALS, INC. interest expense for fiscal 2019 was $931.00K, a 8.09% decline from fiscal 2018.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-06-30 | $2.72M 10-Q · filed 2024-08-13 | $4.54M 10-Q · filed 2024-08-13 | ||
| 2024-03-31 | $1.82M 10-Q · filed 2024-05-07 | |||
| 2023-09-30 | $1.18M 10-Q · filed 2023-11-14 | $1.18M 10-Q · filed 2023-11-14 | ||
| 2022-12-31 | $0.00 10-K · filed 2023-03-16 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $2.00K derived: sum of 2 quarters · filed 2023-03-16 | $2.00K derived: sum of 3 quarters · filed 2023-03-16 | $64.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $2.00K 10-Q · filed 2022-11-09 | $2.00K derived: sum of 2 quarters · filed 2022-11-09 | $64.00K 10-Q · filed 2022-11-09 | $241.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | $62.00K 10-Q · filed 2022-08-11 | $239.00K derived: sum of 3 quarters · filed 2022-05-12 | $389.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-03-31 | $62.00K 10-Q · filed 2022-05-12 | $239.00K derived: sum of 2 quarters · filed 2022-05-12 | $389.00K derived: sum of 3 quarters · filed 2022-05-12 | $531.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $177.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $327.00K derived: sum of 2 quarters · filed 2022-03-17 | $469.00K derived: sum of 3 quarters · filed 2022-03-17 | $628.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $150.00K 10-Q · filed 2021-11-10 | $292.00K derived: sum of 2 quarters · filed 2021-11-10 | $451.00K 10-Q · filed 2021-11-10 | $656.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $142.00K 10-Q · filed 2021-08-12 | $301.00K 10-Q · filed 2021-08-12 | $506.00K derived: sum of 3 quarters · filed 2021-08-12 | $696.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $159.00K 10-Q · filed 2021-05-13 | $364.00K derived: sum of 2 quarters · filed 2021-05-13 | $554.00K derived: sum of 3 quarters · filed 2021-05-13 | $784.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $395.00K derived: sum of 2 quarters · filed 2021-03-18 | $625.00K derived: sum of 3 quarters · filed 2021-03-18 | $931.00K 10-K · filed 2021-03-18 |
| 2019-09-30 | $190.00K 10-Q · filed 2020-11-12 | $420.00K derived: sum of 2 quarters · filed 2020-11-12 | $726.00K 10-Q · filed 2020-11-12 | $1.06M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $230.00K 10-Q · filed 2020-08-13 | $536.00K 10-Q · filed 2020-08-13 | $873.00K derived: sum of 3 quarters · filed 2020-08-13 | $1.18M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $306.00K 10-Q · filed 2020-05-14 | $643.00K derived: sum of 2 quarters · filed 2020-05-14 | $950.00K derived: sum of 3 quarters · filed 2020-05-14 | $1.23M derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | $337.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $644.00K derived: sum of 2 quarters · filed 2020-03-19 | $925.00K derived: sum of 3 quarters · filed 2020-03-19 | $1.01M 10-K · filed 2020-03-19 |
| 2018-09-30 | $307.00K 10-Q · filed 2019-11-12 | $588.00K derived: sum of 2 quarters · filed 2019-11-12 | $676.00K 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $281.00K 10-Q · filed 2019-08-14 | $369.00K 10-Q · filed 2019-08-14 | ||
| 2017-03-31 | $7.00K 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | $6.00K 10-K · filed 2017-03-27 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2015-04-15 | $0.00 derived: sum of 2 quarters · filed 2015-04-15 | $0.00 derived: sum of 3 quarters · filed 2015-04-15 | $0.00 10-K · filed 2015-04-15 |
| 2014-09-30 | $0.00 10-Q/A · filed 2015-04-15 | $0.00 derived: sum of 2 quarters · filed 2015-04-15 | $0.00 10-Q/A · filed 2015-04-15 | $0.00 derived: sum of 4 quarters · filed 2015-04-15 |
| 2014-06-30 | $0.00 10-Q/A · filed 2015-04-15 | $0.00 10-Q/A · filed 2015-04-15 | $0.00 derived: sum of 3 quarters · filed 2015-04-15 | $9.00K derived: sum of 4 quarters · filed 2015-04-15 |
| 2014-03-31 | $0.00 10-Q/A · filed 2015-04-15 | $0.00 derived: sum of 2 quarters · filed 2015-04-15 | $9.00K derived: sum of 3 quarters · filed 2015-04-15 | $137.00K derived: sum of 4 quarters · filed 2015-04-15 |
| 2013-12-31 | $0.00 derived: 10-Q/A 12 month − 10-Q/A 9 month · filed 2015-04-15 | $9.00K derived: sum of 2 quarters · filed 2015-04-15 | $137.00K derived: sum of 3 quarters · filed 2015-04-15 | $233.00K 10-Q/A · filed 2015-04-15 |
| 2013-09-30 | $9.00K 10-Q/A · filed 2015-04-15 | $137.00K derived: sum of 2 quarters · filed 2015-04-15 | $233.00K 10-Q/A · filed 2015-04-15 | |
| 2013-06-30 | $128.00K 10-Q/A · filed 2015-04-15 | $224.00K 10-Q/A · filed 2015-04-15 | ||
| 2013-03-31 | $96.00K 10-Q/A · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |